Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $19.1 million.

  • Anika Therapeutics' Total Current Liabilities fell 2512.06% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year decrease of 2512.06%. This contributed to the annual value of $23.3 million for FY2024, which is 2496.22% down from last year.
  • Anika Therapeutics' Total Current Liabilities amounted to $19.1 million in Q3 2025, which was down 2512.06% from $16.1 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Total Current Liabilities high stood at $47.0 million for Q1 2021, and its period low was $16.1 million during Q2 2025.
  • Its 5-year average for Total Current Liabilities is $27.6 million, with a median of $27.9 million in 2022.
  • In the last 5 years, Anika Therapeutics' Total Current Liabilities soared by 7936.84% in 2021 and then tumbled by 4253.72% in 2022.
  • Anika Therapeutics' Total Current Liabilities (Quarter) stood at $29.8 million in 2021, then decreased by 6.31% to $27.9 million in 2022, then increased by 11.27% to $31.1 million in 2023, then decreased by 24.96% to $23.3 million in 2024, then dropped by 18.09% to $19.1 million in 2025.
  • Its last three reported values are $19.1 million in Q3 2025, $16.1 million for Q2 2025, and $17.9 million during Q1 2025.